Browse by author
Lookup NU author(s): Dr Jessica Richardson, Dr Txuss Martin, Dr Amanda Greenall, Dr Sally Stephens, Dr Laura YatesORCiD, Professor Simon ThomasORCiD
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND).
Background: Venlafaxine is a serotonin noradrenaline reuptake inhibitor used to treat major depressive episodes and anxiety disorders. The primary aim of this study was to investigate spontaneous abortion risks following gestational exposure. Methods: This prospective observational comparative cohort study utilised data collected by the UK Teratology Information Service (UKTIS) between 1995 and 2018. The study sample included 281 venlafaxine exposed pregnancies matched to antidepressant unexposed (n=1,405) and SSRI exposed (n=843) comparator groups. Results: After correction for variation in competing outcome rates and the stage of pregnancy at reporting, no statistically significant differences in the hazard of spontaneous abortion was observed following gestational venlafaxine use compared with either antidepressant unexposed (HR 1.28, 95%CI; 0.850 to 1.94) or SSRI exposed (HR 1.03, 95%CI; 0.681 to 1.57) pregnancies. Conclusions: No conclusive evidence is provided from this study that venlafaxine increases the risk of adverse pregnancy or fetal outcomes.
Author(s): Richardson JL, Martin F, Dunstan H, Greenall A, Stephens S, Yates LM, Thomas SHL
Publication type: Article
Publication status: Published
Journal: Reproductive Toxicology
Year: 2019
Volume: 84
Pages: 108-113
Print publication date: 01/03/2019
Online publication date: 11/01/2019
Acceptance date: 09/01/2019
Date deposited: 10/01/2019
ISSN (print): 0890-6238
ISSN (electronic): 1873-1708
Publisher: Elsevier
URL: https://doi.org/10.1016/j.reprotox.2019.01.003
DOI: 10.1016/j.reprotox.2019.01.003
Altmetrics provided by Altmetric
